SCHEMBL2830636

SCHEMBL2830636

CCCn1c(CN2CCCC2=O)c(C(=O)O)c2cccc(Cl)c2c1=O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.38
ADRA1A P35348 2/20 0.38
ADRA1B P35368 2/20 0.38
ADRA1D P25100 1/20 0.38
GHSR Q92847 2/20 0.38
FABP4 P15090 2/20 0.36
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 3/20 0.35
CMA1 P23946 1/20 0.35
PER2 O15055 1/20 0.35
MEN1 O00255 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2148916 0.88 BDKRB1 (0.40) CNR2FABP4POLBL3MBTL1TSHR
SCHEMBL2674631 0.82 ALDH1A1 (0.40) ADRA1AADRA1BADRA1DPOLBL3MBTL1
SCHEMBL2834063 0.80 CNR2 (0.44) CNR2FABP4POLBTSHRKMT2A
SCHEMBL2149098 0.80 CNR2 (0.40) CNR2POLBL3MBTL1KMT2AMEN1
SCHEMBL2149149 0.78 CYP2C9 (0.41) GHSR
SCHEMBL2833859 0.77 BDKRB1 (0.37) FABP4POLBL3MBTL1TSHRKMT2A
SCHEMBL2832139 0.76 CNR2 (0.55) CNR2TSHRKMT2AMEN1CRHBP
SCHEMBL2831883 0.72 BDKRB1 (0.42) POLBL3MBTL1TSHRKMT2AMEN1
SCHEMBL2830538 0.71 BDKRB1 (0.41) POLBL3MBTL1TSHRKMT2ACMA1
SCHEMBL1717508 0.71 PIK3CD (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
WO-2010028655-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-18 WO claimed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed
WO-2010028655-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 CNR2 359/4885ADRA1A 742/4885ADRA1B 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.